Search results for: Nancy Devlin
Filter search results
Recommendations for Making Outcome-based Payments a Reality in the NHS: An Application to Cancer Drugs
21 February 2019
…burden for individuals, households and society: Estimates and methodology. Journal of Cancer Policy, 15, pp.113–117. DOI. Cubi-Molla, P., Mott, D., Shah, K., Herdman, M., Summers, Y. and Devlin, N. (2018)….
Student Mental Health Research Network (SMaRteN): First Funding Call and Sandpit
26 February 2019
…K., Garside, J., Herdman, M. and Devlin, N., 2018. A Note on the Relationship Between Age and Health-related Quality of Life. Quality of Life Research, pp. 1-5. DOI. RePEc. Morriss,…
Pricing and Paying for Cures: Early Experience with HTA of Gene Therapy in the USA
28 February 2019
…for Cures: Perspectives on Solutions to the “Affordability Issue”. Value in Health, 21(3), pp.276–279. DOI. Hampson, G., Mott, D., Shah, K., and Devlin, N., 2018. Public Preferences for Health Gains…
What Outcomes are Important in Student Mental Health and Wellbeing?
2 May 2019
…website to join the network. For more information about SMaRteN, contact Chris Sampson. Cubí-Mollá, P., Shah, K., Garside, J., Herdman, M. and Devlin, N., 2018. A Note on the Relationship…
Making Outcome-based Payment a Reality in the NHS: Moving to the Next Phase
3 October 2019
…Devlin, N. (2018). Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology. OHE Consulting Report. RePEc. Towse, A. and Garrison, L., 2017. Value assessment…
Are Cost-Effectiveness Thresholds Fit for Purpose for Real-World Decision Making on Access to and Pricing of Pharmaceuticals? A New OHE Paper on Current Methods and Practices, and a Novel Approach for Optimal Thresholds
3 March 2020
…pricing and optimal level of cost-effectiveness threshold: a bargaining approach. OHE Consulting Report, London: Office of Health Economics. (forthcoming) Hernandez-Villafuerte, K., Zamora, B., Parkin, D., Devlin, N. and Towse,…
OHE Authors Develop a Supply and Demand Model of Pharmaceutical Markets to Set Cost-Effectiveness Thresholds to Maximise and Distribute Social Welfare
15 June 2020
…Report. London: Office of Health Economics. Hernandez-Villafuerte, K., Zamora, B., Parkin, D., Devlin, N. and Towse, A., 2019. Exploring variations in the opportunity cost cost-effectiveness threshold by clinical area: Results…
NICE ‘Optimised’ Recommendations: What Do They Mean for Patient Access?
30 July 2020
…2015 and 2019. In doing so, we update previous research in this area (O’Neill and Devlin, 2010). In about two-thirds (65%) of optimised recommendations for which information was available, NICE…
Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?
16 June 2021
…British Pharmaceutical Industry as a research grant. Citation Cubi-Molla, P., Buxton, M. & Devlin, N. Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions…